ReviewPediatric pulmonology2025
Cystic Fibrosis Care in South Africa: Facing the Challenge of Diversity and Inequality.
Review in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evolving Cystic Fibrosis Therapy: The Good, the Sad, and the Hopeful.Children (Basel, Switzerland) · 2026Review
- Cystic fibrosis transmembrane conductance regulator modulator therapy and lived experiences in South Africa: A mixed-methods study.The South African journal of physiotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Low-and-middle-income countries (LMIC) like South Africa (SA) were left behind with advancements in cystic fibrosis (CF) care that followed re-imbursement agreements in high-income countries of CF transmembrane regulator protein modulators (CFTRm) for the treatment of CF. A combination of global monopoly, patent protection by international trade agreements and delays in regulatory approvals are factors keeping these transformative drugs out of reach for many LMIC due to their high cost. Unequal and delayed access to CFTRm is amplifying existing disparities in CF care and outcomes worldwide, including SA where currently only 200 (50%) of the 400 eligible people have access to CFTRm. However, the SA experience demonstrated how health professionals, legal experts and global CF community activists can collaborate to mobilize local and international resources to advocate for affordable and equal access to CFTRm In this paper we describe the journey followed in SA to overcome some of these inequalities and challenges and highlight the current and future impact on CF care in SA that may have much in common with other LMIC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.